Drug Detail
Information about BRAFTOVI
Generic Name |
Encorafenib | |
|---|---|---|
IND |
||
Brand Name (US) |
BRAFTOVI | |
Manufacturer |
Array Biopharma | |
Drug Type |
Kinase inhibitor | |
Delivery |
Oral | |
Approval Status |
Approved for a non-GIST cancer | |
Indications |
Melanoma with BRAF mutations | |
Overall Strategy |
Oncogenic Signal Path Based | |
Strategy |
Block BRAF | |
Drug Category |
BRAF Inhibitor + MEK Inhibitor | |
Approved in combination with MEDTOVI (binimetinib) for advanced melanoma with BRAFV600E or BRAFV600K mutations.
Links |
|
|
ARRAY BIOPHARMA ANNOUNCES FDA APPROVAL OF BRAFTOVI™ (ENCORAFENIB) IN COMBINATION WITH MEKTOVI® (BINIMETINIB) |
|
BraftoviMektovi.com website |
Trials of this drug |
|
Trial results |
|
Search for this drug/combination in: